The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-kB positive feedback loop in peripheral T-cell lymphoma

Blood

Volumn 125, Issue 20, 2015, Pages 3118-3127

  Boddicker, Rebecca L ^a   Kip, N Sertac ^a   Xing, Xiaoming ^a,b   Zeng, Yu ^a,c   Yang, Zhi Zhang ^a   Lee, Jeong Heon ^a   Almada, Luciana L ^a   Elsawa, Sherine F ^a   Knudson, Ryan A ^a   Law, Mark E ^a   Ketterling, Rhett P ^a   Cunningham, Julie M ^a   Wu, Yanhong ^a   Maurer, Matthew J ^a   O'Byrne, Megan M ^a   Cerhan, James R ^a   Slager, Susan L ^a   Link, Brian K ^d   Porcher, Julie C ^a   Grote, Deanna M ^a   Jelinek, Diane F ^a,e   Dogan, Ahmet ^a   Ansell, Stephen M ^a   Fernandez Zapico, Martin E ^a   Feldman, Andrew L ^a   more..

^a MAYO CLINIC   (United States)

^b QINGDAO UNIVERSITY   (China)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; MYC PROTEIN; TRANSCRIPTION FACTOR RELB; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4;

ADULT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL T CELL LYMPHOMA; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN FUNCTION; T-CELL LYMPHOMA CELL LINE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; AGED; BIOLOGICAL MODEL; COPY NUMBER VARIATION; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETICS; GERM CELL; METABOLISM; ONCOGENE MYC; TUMOR CELL LINE;

ADULT; AGED; ANTIGENS, CD30; CELL LINE, TUMOR; CELL PROLIFERATION; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GERM CELLS; HUMANS; INTERFERON REGULATORY FACTORS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NF-KAPPA B; POLYMORPHISM, GENETIC; TRANSCRIPTION, GENETIC;

EID: 84964695221     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-578575     Document Type: Article

References (69)

1. Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control. 2008; 19(8):841-858.
2. Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(5):511-519.
3. Savage KJ. Update: peripheral T-cell lymphomas. Curr Hematol Malig Rep. 2011;6(4):222-230.
4. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112(13):4808-4817.
5. Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitorsfor cancer therapy. Med Res Rev. 2008;28(3): 372-412.
6. Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia. 2009;23(3):574-580.
7. Cauwelier B, Dastugue N, Cools J, et al. Molecular cytogenetic study of 126 unselected T-ALL cases reveals high incidence of TCRbeta locus rearrangements and putative new T-cell oncogenes. Leukemia. 2006;20(7): 1238-1244.
8. De Silva NS, Simonetti G, Heise N, Klein U. The diverse roles of IRF4 in late germinal center B-cell differentiation. Immunol Rev. 2012;247(1):73-92.
9. Ochiai K, Maienschein-Cline M, Simonetti G, et al. Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity. 2013;38(5):918-929.
10. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008; 454(7201):226-231.
11. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res. 2009;15(9):2954-2961.
12. Tsuboi K, Iida S, Inagaki H, et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia. 2000;14(3): 449-456.
13. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95(6):2084-2092.
14. Bisig B, de Reyniès A, Bonnet C, et al. Molecular and phenotypic features are shared by CD30-positive peripheral T-cell lymphomas [published online ahead of print May 28, 2013]. Haematologica.
15. Vatolin S, Khan SN, Reu FJ. Direct chromatin PCR (DC-PCR): hypotonic conditions allow differentiation of chromatin states during thermal cycling. PLoS ONE. 2012;7(9):e44690.
16. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
17. Charbonneau B, Wang AH, Maurer MJ, et al. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol Immunother. 2013;62(9):1475-1484.
18. Do TN, Ucisik-Akkaya E, Davis CF, Morrison BA, Dorak MT. An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males. Biochim Biophys Acta. 2010;1802(2):292-300.
19. Watanabe M, Ogawa Y, Itoh K, et al. Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma. Lab Invest. 2008;88(1):48-57.
20. Imaizumi Y, Kohno T, Yamada Y, et al. Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia. Jpn J Cancer Res. 2001;92(12): 1284-1292.
21. Man K, Miasari M, Shi W, et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat Immunol. 2013;14(11):1155-1165.
22. Verdelli D, Nobili L, Todoerti K, et al. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. Hematol Oncol. 2009;27(1):23-30.
23. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360): 298-303.
24. Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012; 120(5):1077-1086.
25. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2008;40(10): 1204-1210.
26. Damgaard RB, Gyrd-Hansen M. Inhibitor of apoptosis (IAP) proteins in regulation of inflammation and innate immunity. Discov Med. 2011;11(58):221-231.
27. Bonvini P, Zorzi E, Basso G, Rosolen A. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-301 anaplastic large cell lymphoma. Leukemia. 2007;21(4):838-842.
28. Buchan SL, Al-Shamkhani A. Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-κB signaling. PLoS ONE. 2012;7(9): e45244.
29. Hirsch B, Hummel M, Bentink S, et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol. 2008;172(2):510-520.
30. Nishikori M, Ohno H, Haga H, Uchiyama T. Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3. Cancer Sci. 2005; 96(8):487-497.
31. Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem. 2007;282(14): 10252-10262.
32. Li P, Spolski R, Liao W, et al. BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature. 2012;490(7421):543-546.
33. Glasmacher E, Agrawal S, Chang AB, et al. A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes. Science. 2012;338(6109):975-980.
34. Croager EJ, Muir TM, Abraham LJ. Analysis of the human and mouse promoter region of the non-Hodgkin's lymphoma-associated CD30 gene. J Interferon Cytokine Res. 1998;18(11):915-920.
35. Zheng W, Liu D, Fan X, et al. Potential therapeutic biomarkers in plasma cell myeloma: a flow cytometry study. Cytometry B Clin Cytom. 2013;84B(4):222-228.
36. Weilemann A, Grau M, Erdmann T, et al. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood. 2015;125(1):124-132.
37. Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997;17(2): 226-230.
38. Michaux L, Wlodarska I, Rack K, et al. Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in "unmutated" B-CLL. Leukemia. 2005;19(1):77-82.
39. Salaverria I, Philipp C, Oschlies I, et al; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe; German High-Grade Lymphoma Study Group; Berlin-Frankfurt-Münster-NHL trial group. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011;118(1):139-147.
40. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511.
41. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
42. Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013; 121(14):2715-2724.
43. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109(7): 2700-2707.
44. Martínez-Delgado B, Cuadros M, Honrado E, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia. 2005;19(12):2254-2263.
45. Odqvist L, Sánchez-Beato M, Montes-Moreno S, et al. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells. Clin Cancer Res. 2013;19(9):2319-2330.
46. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphomadefined by gene expression profiling. Clin Cancer Res. 2005;11(1):28-40.
47. Saito M, Gao J, Basso K, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell. 2007; 12(3):280-292.
48. Sharma S, Grandvaux N, Mamane Y, et al. Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells. J Immunol. 2002;169(6):3120-3130.
49. Ramos JC, Ruiz P Jr, Ratner L, et al. IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood. 2007;109(7): 3060-3068.
50. Grumont RJ, Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferonregulated gene expression by rel/nuclear factor kappaB. J Exp Med. 2000;191(8):1281-1292.
51. Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28(3):525-542.
52. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12):1861-1874.
53. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(6):690-697.
54. Kim SJ, Yoon DH, Kang HJ, et al; Consortium for Improving Survival of Lymphoma (CISL) investigators. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012;48(17):3223-3231.
55. Evens AM, Rosen ST, Helenowski I, et al. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br J Haematol. 2013;163(1):55-61.
56. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293-4297.
57. Smale ST. Dimer-specific regulatory mechanisms within the NF-κB family of transcription factors. Immunol Rev. 2012;246(1):193-204.
58. Kwon H, Thierry-Mieg D, Thierry-Mieg J, et al. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity. 2009;31(6):941-952.
59. Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF)5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem. 1997;272(4): 2042-2045.
60. Guo F, Sun A, Wang W, et al. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol. 2009;46(13): 2441-2448.
61. Lee SY, Park CG, Choi Y. T cell receptordependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptorassociated factors. J Exp Med. 1996;183(2): 669-674.
62. Schneider C, Hübinger G. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma. 2002;43(7): 1355-1366.
63. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
64. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
65. Gathany AH, Hartge P, Davis S, et al. Relationship between interferon regulatory factor4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma. Cancer Causes Control. 2009;20(8):1291-1302.
66. Praetorius C, Grill C, Stacey SN, et al. A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell. 2013;155(5): 1022-1033.
67. Wright CW, Duckett CS. The aryl hydrocarbon nuclear translocator alters CD30-mediatedNF-kappaB-dependent transcription. Science. 2009;323(5911):251-255.
68. Lehtonen A, Veckman V, Nikula T, et al. Differential expression of IFN regulatory factor 4 gene in human monocyte-derived dendritic cells and macrophages. J Immunol. 2005;175(10):6570-6579.
69. Zhang X, Tao Y, Troiani L, Markovic-Plese S. Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD41 T cells derived from patients with multiple sclerosis. J Immunol. 2011;187(6):3431-3437.